Steward Partners Investment Advisory’s Akebia Therapeutics AKBA Stock Holding History

Steward Partners Investment Advisory’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-374	Closed	-$1K	–	3272
2021 Q4	$1K	Buy	+374	New	+$1.02K	﹤0.01%	3067
2020 Q3	–	Sell	-3,000	Closed	-$41K	–	2725
2020 Q2	$41K	Hold	3,000	–	–	﹤0.01%	1491
2020 Q1	$22K	Sell	3,000 -300	-9%	-$2.33K	﹤0.01%	1570
2019 Q4	$20K	Hold	3,300	–	–	﹤0.01%	1761
2019 Q3	$12K	Hold	3,300	–	–	﹤0.01%	1897
2019 Q2	$15K	Buy	+3,300	New	+$18.8K	﹤0.01%	1803
2018 Q4	–	Sell	-800	Closed	-$7K	–	815
2018 Q3	$7K	Sell	800 -160	-17%	-$1.43K	﹤0.01%	1998
2018 Q2	$10K	Hold	960	–	–	﹤0.01%	1725
2018 Q1	$9K	Sell	960 -400	-29%	-$5.59K	﹤0.01%	1594
2017 Q4	$20K	Buy	+1,360	New	+$22.6K	﹤0.01%	1106

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Steward Partners Investment Advisory's AKBA Position: Q1 2022 in Review

Steward Partners Investment Advisory sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 374 shares — an estimated $1K sold.

Steward Partners Investment Advisory first reported a position in AKBA in Q4 2017 and held it in 10 quarters. The position peaked at $41K in Q2 2020. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

Steward Partners Investment Advisory reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
Steward Partners Investment Advisory sold 374 Akebia Therapeutics shares in Q1 2022, an estimated $1K.
Steward Partners Investment Advisory first reported a position in Akebia Therapeutics in Q4 2017 and held it in 10 quarters.
Steward Partners Investment Advisory's Akebia Therapeutics position peaked at $41K in Q2 2020.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2022, filed 2 May 2022.